BURLINGTON, Mass., Nov. 5, 2014 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis market will experience robust growth over the next decade as sales increase from $6.6 billion in 2013 to $10.7 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The continued uptake of Janssen's interleukin (IL)-12/23 inhibitor Stelara in earlier lines of therapy and the entry of therapies with novel mechanisms of action (notably the IL-17 inhibitors), will drive sales growth. Stelara is forecast to achieve major-market sales of approximately $2.4 billion in 2023, representing nearly 22 percent of total psoriasis sales.

Other key findings from the Pharmacor report entitled Psoriasis:

  • Emerging agents will drive sales: The launches and uptake of several emerging agents—the IL-17 inhibitors (Novartis's secukinumab, Eli Lilly's ixekizumab, and Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab), and Pfizer's Jak inhibitor Xeljanz—will also drive sales over the 2013-2023 forecast period.
  • Competition from emerging biologics: TNF-alpha inhibitors and Stelara will experience competition from emerging biologics and oral agents with novel mechanisms of action. Although concerns about their long-term safety profiles will restrict uptake initially, the emerging IL-17 inhibitors, Xeljanz, and emerging IL-23 inhibitors (Sun Pharma/Merck's tildrakizumab and Janssen's guselkumab), will increase competition within the TNF-alpha-refractory space.
  • Oral therapies will expand treatment options: Although the perceived lower efficacy of Xeljanz and concerns about the drug's safety profile will restrict its market potential, Xeljanz will also compete for use in the TNF-alpha-refractory space. Another oral agent, Celgene's phosphodiesterase-4 inhibitor Otezla, has recently been approved for the treatment of psoriasis (in addition to psoriatic arthritis), and will present an alternative to conventional systemic therapies as an interim step prior to biological therapy.

Comments from Decision Resources Group Senior Business Insights Analyst Kathryn Beane:

  • "Thought leaders are particularly interested in the emerging IL-17 inhibitors, which have shown impressive efficacy in late-stage trials, with similar efficacy to the most potent current therapy for psoriasis—Remicade (Janssen/Merck/Mitsubishi Tanabe Pharma). The efficacy and safety of emerging IL-17 inhibitors and IL-23 inhibitors are being evaluated in head-to-head clinical trials with current biologics, which will increase dermatologists' confidence adopting these new therapies."
  • "Although these agents will initially compete in the TNF-alpha-refractory population and in patients who lose response to Stelara, as their long-term safety profiles become more established, physicians will be comfortable prescribing them earlier—potentially as first-line biologics—in the treatment algorithm."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Asia Pacific Electrophysiology Mapping and Ablation Device Market Will Reach Nearly $1.3 Billion by 2023

View Now